Valneva (NASDAQ:VALN) Shares Gap Down on Analyst Downgrade

Shares of Valneva SE (NASDAQ:VALN) gapped down before the market opened on Tuesday after Guggenheim lowered their price target on the stock from $17.00 to $15.00. The stock had previously closed at $7.43, but opened at $7.28. Guggenheim currently has a buy rating on the stock. Valneva shares last traded at $7.03, with a volume of 5,928 shares.

Separately, HC Wainwright reissued a “buy” rating and issued a $17.00 target price on shares of Valneva in a research report on Friday, March 21st.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Valneva stock. ABC Arbitrage SA acquired a new position in shares of Valneva SE (NASDAQ:VALN) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 19,244 shares of the company’s stock, valued at approximately $84,000. 11.39% of the stock is currently owned by hedge funds and other institutional investors.

Valneva Trading Up 1.3 %

The firm’s fifty day simple moving average is $6.51 and its 200 day simple moving average is $5.60. The stock has a market capitalization of $581.83 million, a P/E ratio of -55.08 and a beta of 1.93. The company has a debt-to-equity ratio of 0.70, a quick ratio of 2.25 and a current ratio of 2.78.

Valneva (NASDAQ:VALN) last announced its quarterly earnings data on Thursday, March 20th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.32). Valneva had a negative net margin of 4.35% and a negative return on equity of 3.93%. The firm had revenue of $56.48 million during the quarter, compared to the consensus estimate of $55.64 million. As a group, equities research analysts forecast that Valneva SE will post 0.13 EPS for the current fiscal year.

About Valneva

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.